chlorthalidone has been researched along with Stroke in 23 studies
Chlorthalidone: A benzenesulfonamide-phthalimidine that tautomerizes to a BENZOPHENONES form. It is considered a thiazide-like diuretic.
Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
Excerpt | Relevance | Reference |
---|---|---|
"Serum uric acid independently predicts cardiovascular events in older persons with isolated systolic hypertension." | 9.09 | Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). ( Applegate, WB; Di Bari, M; Franse, LV; Pahor, M; Shorr, RI; Somes, GW; Wan, JY, 2000) |
"Stroke: common 'GG' homozygotes had higher risk on lisinopril versus amlodipine [hazard ratio (HR)=1." | 5.14 | Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study. ( Arnett, DK; Boerwinkle, E; Davis, BR; Eckfeldt, JH; Ford, CE; Leiendecker-Foster, C; Lynch, AI, 2009) |
"The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) was a randomized, double-blind, active, controlled clinical trial conducted to determine whether newer antihypertensive agents, including doxazosin, an alpha-blocker, differ from chlorthalidone, a diuretic, with respect to coronary heart disease (CHD) and other cardiovascular disease (CVD) events in hypertensive patients at high risk of CHD." | 5.10 | Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ( , 2003) |
"Serum uric acid independently predicts cardiovascular events in older persons with isolated systolic hypertension." | 5.09 | Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). ( Applegate, WB; Di Bari, M; Franse, LV; Pahor, M; Shorr, RI; Somes, GW; Wan, JY, 2000) |
"The aim of this study was to investigate whether there is a genotype-by-treatment interaction in patients experiencing stroke and treated with one of three antihypertensive drugs, that is chlorthalidone, amlodipine, or lisinopril." | 3.80 | Pharmacogenetic effects of 'candidate gene complexes' on stroke in the GenHAT study. ( Arnett, DK; Boerwinkle, E; Davis, BR; Eckfeldt, JH; Ford, CE; Irvin, MR; Sørensen, IF; Sørensen, P; Vazquez, AI, 2014) |
"There is significant controversy around whether chlorthalidone (CTD) is superior to hydrochlorothiazide (HCTZ) in hypertension management." | 3.77 | Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. ( Bleske, BE; Dorsch, MP; Erickson, SR; Gillespie, BW; Weder, AB, 2011) |
"Asymptomatic carotid stenosis is when this narrowing occurs in people without a history or symptoms of this disease." | 3.01 | Pharmacological interventions for asymptomatic carotid stenosis. ( Cassola, N; Clezar, CN; Flumignan, CD; Flumignan, RL; Nakano, LC; Trevisani, VF, 2023) |
"Incident stroke was significantly decreased by treatment in the Systolic Hypertension in Elderly Program (SHEP) Trial, but the reduction in fatal events was not statistically significant." | 2.73 | Long-term fatal outcomes in subjects with stroke or transient ischemic attack: fourteen-year follow-up of the systolic hypertension in the elderly program. ( Davis, BR; Kostis, JB; Patel, AB; Pressel, SL; Shea, ML; Wilson, AC, 2008) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 13 (56.52) | 29.6817 |
2010's | 8 (34.78) | 24.3611 |
2020's | 2 (8.70) | 2.80 |
Authors | Studies |
---|---|
Itoga, NK | 1 |
Tawfik, DS | 1 |
Montez-Rath, ME | 1 |
Chang, TI | 1 |
Clezar, CN | 1 |
Flumignan, CD | 1 |
Cassola, N | 1 |
Nakano, LC | 1 |
Trevisani, VF | 1 |
Flumignan, RL | 1 |
Haywood, LJ | 3 |
Davis, BR | 9 |
Piller, LB | 2 |
Simpson, LM | 1 |
Ghosh, A | 1 |
Einhorn, PT | 1 |
Ford, CE | 6 |
Probstfield, JL | 4 |
Soliman, EZ | 1 |
Wright, JT | 3 |
Oparil, S | 3 |
Cushman, WC | 2 |
Furberg, CD | 1 |
Habib, GB | 2 |
Margolis, K | 1 |
Whelton, PK | 2 |
Sørensen, IF | 1 |
Vazquez, AI | 1 |
Irvin, MR | 1 |
Sørensen, P | 1 |
Boerwinkle, E | 3 |
Eckfeldt, JH | 3 |
Arnett, DK | 3 |
Yamal, JM | 1 |
Alderman, MH | 1 |
Calhoun, DA | 1 |
Fendley, HF | 1 |
Franklin, SS | 1 |
Pressel, SL | 2 |
Sastrasinh, S | 1 |
Thomopoulos, C | 1 |
Parati, G | 1 |
Zanchetti, A | 1 |
Bath, PM | 1 |
Geeganage, CM | 1 |
Gray, LJ | 1 |
Lynch, AI | 2 |
Leiendecker-Foster, C | 2 |
Dorsch, MP | 1 |
Gillespie, BW | 1 |
Erickson, SR | 1 |
Bleske, BE | 1 |
Weder, AB | 1 |
Zhang, X | 1 |
Rahman, M | 1 |
Cutler, JA | 1 |
Barzilay, JI | 1 |
Brown, CD | 1 |
Colon, PJ | 1 |
Fine, LJ | 1 |
Grimm, RH | 1 |
Gupta, AK | 1 |
Baimbridge, C | 1 |
Henriquez, MA | 1 |
Ilamaythi, E | 1 |
Preston, R | 1 |
Scott, I | 1 |
Stowasser, M | 1 |
Düsing, R | 1 |
Diener, HC | 1 |
Rahn, KH | 1 |
Kuwajima, I | 1 |
Yusuf, S | 1 |
Patel, AB | 1 |
Kostis, JB | 1 |
Wilson, AC | 1 |
Shea, ML | 1 |
Perry, HM | 1 |
Price, TR | 1 |
Applegate, WB | 2 |
Fields, WS | 1 |
Guralnik, JM | 1 |
Kuller, L | 1 |
Pressel, S | 1 |
Stamler, J | 1 |
Koval, PG | 1 |
McDiarmid, T | 1 |
Franse, LV | 1 |
Pahor, M | 1 |
Di Bari, M | 1 |
Shorr, RI | 1 |
Wan, JY | 1 |
Somes, GW | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
[NCT00000542] | Phase 3 | 0 participants | Interventional | 1993-08-31 | Completed | ||
Pharmacological Association of the Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism on Blood Pressure and Cardiovascular Risk in Relation to Anti-hypertensive Treatment[NCT00006294] | 37,939 participants (Actual) | Observational | 1999-09-30 | Completed | |||
[NCT00000514] | Phase 3 | 0 participants | Interventional | 1984-06-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
4 reviews available for chlorthalidone and Stroke
Article | Year |
---|---|
Pharmacological interventions for asymptomatic carotid stenosis.
Topics: Aspirin; Atherosclerosis; Atorvastatin; Carotid Stenosis; Chlorthalidone; Fluvastatin; Hemorrhage; H | 2023 |
Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs--overview and meta-analyses.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2015 |
[Recent intervention studies with antihypertensive drugs and their influence on guidelines].
Topics: Adrenergic beta-Antagonists; Aged; Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Convert | 2003 |
[ALLHAT trial--antithesis to the overuse of vasodilating antihypertensive drugs].
Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypert | 2004 |
11 trials available for chlorthalidone and Stroke
Article | Year |
---|---|
Risk Factors Influencing Outcomes of Atrial Fibrillation in ALLHAT.
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Atrial Fibrillation; Atrial Flutter; C | 2018 |
Mortality and morbidity during and after Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: results by sex.
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Chlorthalido | 2013 |
Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHAT.
Topics: Age Factors; Aged; Amlodipine; Cause of Death; Chlorthalidone; Confidence Intervals; Dose-Response R | 2014 |
Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2009 |
Pharmacogenetic association of NOS3 variants with cardiovascular disease in patients with hypertension: the GenHAT study.
Topics: Aged; Alleles; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Double- | 2012 |
Pharmacogenetic association of NOS3 variants with cardiovascular disease in patients with hypertension: the GenHAT study.
Topics: Aged; Alleles; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Double- | 2012 |
Pharmacogenetic association of NOS3 variants with cardiovascular disease in patients with hypertension: the GenHAT study.
Topics: Aged; Alleles; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Double- | 2012 |
Pharmacogenetic association of NOS3 variants with cardiovascular disease in patients with hypertension: the GenHAT study.
Topics: Aged; Alleles; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Double- | 2012 |
Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR.
Topics: Amlodipine; Antihypertensive Agents; Canada; Chlorthalidone; Chronic Disease; Coronary Disease; Doub | 2012 |
Are thiazide diuretics preferred as first-line therapy for hypertension? An appraisal of The Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Benzothiadiazines; Blood Chemical Analysis; Chlorthalidone; Diuretics; Dose-Respon | 2003 |
Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Blood Pressure; Chlorthalidone; Coronary Dise | 2003 |
Long-term fatal outcomes in subjects with stroke or transient ischemic attack: fourteen-year follow-up of the systolic hypertension in the elderly program.
Topics: Adult; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Cause of Death; Chlorthalidone; F | 2008 |
Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP).
Topics: Aged; Antihypertensive Agents; Atenolol; Brain Ischemia; Cerebral Hemorrhage; Chlorthalidone; Double | 2000 |
Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP).
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Biomarkers; Cardiovascular Dis | 2000 |
8 other studies available for chlorthalidone and Stroke
Article | Year |
---|---|
Contributions of Systolic and Diastolic Blood Pressures to Cardiovascular Outcomes in the ALLHAT Study.
Topics: Aged; Amlodipine; Blood Pressure; Blood Pressure Determination; Cardiovascular Diseases; Chlorthalid | 2021 |
Pharmacogenetic effects of 'candidate gene complexes' on stroke in the GenHAT study.
Topics: Aged; Amlodipine; Chlorthalidone; Female; Genotype; Humans; Lisinopril; Male; Middle Aged; Pharmacog | 2014 |
Ordinal reanalysis of the SHEP trial.
Topics: Antihypertensive Agents; Chlorthalidone; Clinical Trials as Topic; Data Interpretation, Statistical; | 2008 |
Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis.
Topics: Adult; Angina Pectoris; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Cholesterol; Heart | 2011 |
[The new (old) knowledge in primary prevention of stroke. It depends on lowering of blood pressure].
Topics: Adrenergic alpha-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2003 |
[Primary prevention of stroke. What helps--what does not help? The guidelines of the German Society of Neurology briefly summarized].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Alcohol Drinking; Anticholesteremic | 2003 |
Preventing vascular events due to elevated blood pressure.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Comorbidity; Doxazosin; Drug Thera | 2006 |
How effective is doxazosin compared with chlorthalidone in the treatment of hypertension?
Topics: Aged; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Coronary Disease; Diuretics; | 2000 |